Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

198 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials.
Beck EJ, Sherry AD, Florez MA, Kouzy R, Abi Jaoude J, Lin TA, Miller AM, Passy AH, Kupferman GS, Patel RR, Chino F, Higbie VS, Parseghian CM, Overman MJ, Minsky BD, Thomas CR Jr, Tang C, Msaouel P, Ludmir EB. Beck EJ, et al. Among authors: msaouel p. Cancer Res Commun. 2024 Aug 1;4(8):2183-2188. doi: 10.1158/2767-9764.CRC-24-0265. Cancer Res Commun. 2024. PMID: 39099199 Free PMC article.
Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial.
Tang C, Msaouel P, Hara K, Choi H, Le V, Shah AY, Wang J, Jonasch E, Choi S, Nguyen QN, Das P, Prajapati S, Yu Z, Khan K, Powell S, Murthy R, Sircar K, Tannir NM. Tang C, et al. Among authors: msaouel p. Lancet Oncol. 2021 Dec;22(12):1732-1739. doi: 10.1016/S1470-2045(21)00528-3. Epub 2021 Oct 28. Lancet Oncol. 2021. PMID: 34717797 Clinical Trial.
Improving the clinical meaning of surrogate endpoints: An empirical assessment of clinical progression in phase III oncology trials.
Sherry AD, Lin TA, McCaw ZR, Beck EJ, Kouzy R, Abi Jaoude J, Passy AH, Miller AM, Kupferman GS, Fuller CD, Thomas CR Jr, Koay EJ, Tang C, Msaouel P, Ludmir EB. Sherry AD, et al. Among authors: msaouel p. Int J Cancer. 2024 Dec 1;155(11):1939-1943. doi: 10.1002/ijc.35129. Epub 2024 Aug 13. Int J Cancer. 2024. PMID: 39138841
A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer.
Campbell MT, Shah AY, Msaouel P, Tannir NM, Siefker-Radtke AO, Kamat AM, Navai N, Dinney CPN, Rao P, Guo CC, Sheth RA, Venkatesan AM, Tidwell RS, Yadav SS, Gu A, Chen H, Macaluso M, Duan F, Basu S, Jindal S, Sharma P. Campbell MT, et al. Among authors: msaouel p. Cancer Res Commun. 2024 Sep 1;4(9):2444-2453. doi: 10.1158/2767-9764.CRC-24-0237. Cancer Res Commun. 2024. PMID: 39207194 Free PMC article.
Loss of ARID1A Promotes Epithelial-Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress.
Tomihara H, Carbone F, Perelli L, Huang JK, Soeung M, Rose JL, Robinson FS, Lissanu Deribe Y, Feng N, Takeda M, Inoue A, Poggetto ED, Deem AK, Maitra A, Msaouel P, Tannir NM, Draetta GF, Viale A, Heffernan TP, Bristow CA, Carugo A, Genovese G. Tomihara H, et al. Among authors: msaouel p. Cancer Res. 2021 Jan 15;81(2):332-343. doi: 10.1158/0008-5472.CAN-19-3922. Epub 2020 Nov 6. Cancer Res. 2021. PMID: 33158812 Free PMC article.
198 results